Nobel Laureate Professor Martin Evans and Ajan Reginald, the former Global Head of Emerging Technologies at Roche, founded Cell Therapy Limited (CTL) in 2009. CTL’s mission is to develop regenerative medicines for life – to discover and develop regenerative medicines to treat life-threatening and life-altering diseases. The first product from the Company’s technology platform, HeartcelTM has successfully shown in Phase II to regenerate the heart in end-stage heart failure patients, improving heart function, decreasing mortality and improving patients’ quality of life. The Company applies its extensive regenerative medicine patent portfolio and expertise to areas of high unmet clinical need. CTL has additional clinical and preclinical programs in tendon injury, dermatology, oncology, diabetes and liver fibrosis.
Be the first to comment